Canada - English - Health Canada

auro pharma inc - fulvestrant - solution - 50mg - fulvestrant 50mg

Canada - English - Health Canada

formative pharma inc. - fulvestrant - solution - 50mg - fulvestrant 50mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fulvestrant 50 mg/ml;  ;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml     excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant ever pharma is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: · previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) -

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - fulvestrant 50 mg in 1 ml - monotherapy faslodex is indicated for the treatment of: combination therapy faslodex is indicated for the treatment of: faslodex is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with faslodex [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, faslodex can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data] . advise pregnant women of the potential risk to a fetus. the estimated backg

United States - English - NLM (National Library of Medicine)

sandoz inc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2)] . risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data ]. advise pregnant women of the potential

Israel - English - Ministry of Health

pharmalogic ltd - fulvestrant - solution for injection - fulvestrant 50 mg / 1 ml - fulvestrant - fulvestrant ever pharma 250 mg is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy,or* disease progression on endocrine therapy.combination therapy with palbociclib: fulvestrant ever pharma 250 mg is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)- negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - fulvestrant 250 mg/5 ml - solution for injection - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - fulvestrant 250 mg/5 ml - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant